Cross Reactive Siglec Antibodies

Patent No. EP3191517 (titled "Cross Reactive Siglec Antibodies") was filed by Innate Pharma on Sep 9, 2015. The application was issued on Nov 4, 2020.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
GRAF VON STOSCH	Aug 3, 2021	-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Jun 15, 2023
Communication to the parties concerning the termination of the opposition proceedings (opponent)
Jun 15, 2023
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Jun 12, 2023
Termination of the opposition proceedings with revocation of patent
Mar 6, 2023
Advice of delivery
Mar 1, 2023
Advice of delivery
Mar 1, 2023
Decision of the Opposition Division and instruction
Mar 1, 2023
Decision revoking the European patent
Mar 1, 2023
Decision revoking the European patent
Mar 1, 2023
Grounds for the decision (Annex) - opposition
Mar 1, 2023
Means of redress
Mar 1, 2023
Transmittal of decision / summons - opposition
Mar 1, 2023
Transmittal of decision / summons - opposition
Feb 28, 2023
Advice of delivery
Feb 27, 2023
Advice of delivery
Feb 24, 2023
Notification concerning the date of oral proceedings
Feb 24, 2023
Notification concerning the date of oral proceedings
Feb 22, 2023
Brief communication - Opposition proceedings
Feb 17, 2023
(Electronic) Receipt
Feb 17, 2023
Letter accompanying subsequently filed items
Feb 17, 2023
Withdrawal of a request for oral proceedings
Dec 12, 2022
Notification concerning the date of oral proceedings
Dec 12, 2022
Notification concerning the date of oral proceedings
Apr 12, 2022
Advice of delivery
Apr 8, 2022
Advice of delivery
Apr 8, 2022
Advice of delivery
Apr 5, 2022
Annex to the communication - opposition
Apr 5, 2022
Citation in opposition procedure - 016
Apr 5, 2022
Information concerning oral proceedings
Apr 5, 2022
Summons to attend oral proceedings
Apr 5, 2022
Summons to attend oral proceedings
Apr 5, 2022
Transmittal of decision / summons - opposition
Apr 5, 2022
Transmittal of decision / summons - opposition
Apr 4, 2022
Brief communication - Opposition proceedings
Mar 30, 2022
Information about the result of oral proceedings
Mar 29, 2022
(Electronic) Receipt
Mar 29, 2022
Letter accompanying subsequently filed items
Mar 29, 2022
Letter regarding the opposition procedure (no time limit)
Dec 22, 2021
Brief communication - Opposition proceedings
Dec 17, 2021
(Electronic) Receipt
Dec 17, 2021
Auxiliary request during Opposition procedure
Dec 17, 2021
Auxiliary request during Opposition procedure
Dec 17, 2021
Auxiliary request during Opposition procedure
Dec 17, 2021
Auxiliary request during Opposition procedure - 01
Dec 17, 2021
Auxiliary request during Opposition procedure - 02
Dec 17, 2021
Auxiliary request during Opposition procedure - 03
Dec 17, 2021
Citation in opposition procedure - 014
Dec 17, 2021
Citation in opposition procedure - 015
Dec 17, 2021
Consolidated list of cited opposition documents
Dec 17, 2021
Letter accompanying subsequently filed items
Dec 17, 2021
Reply of the patent proprietor to the notice(s) of opposition
Sep 27, 2021
Communication of amended entries concerning the representative
Aug 19, 2021
Communication of a notice of opposition and request to file observations
Aug 19, 2021
Notice of further oppositions to opponent(s)
Aug 9, 2021
Communication of a notice of opposition - first information to patent proprietor
Aug 3, 2021
(Electronic) Receipt
Aug 3, 2021
Citation in opposition procedure - 001
Aug 3, 2021
Citation in opposition procedure - 001
Aug 3, 2021
Citation in opposition procedure - 002
Aug 3, 2021
Citation in opposition procedure - 003
Aug 3, 2021
Citation in opposition procedure - 004
Aug 3, 2021
Citation in opposition procedure - 005
Aug 3, 2021
Citation in opposition procedure - 006
Aug 3, 2021
Citation in opposition procedure - 007
Aug 3, 2021
Citation in opposition procedure - 008
Aug 3, 2021
Citation in opposition procedure - 009
Aug 3, 2021
Citation in opposition procedure - 010
Aug 3, 2021
Citation in opposition procedure - 012
Aug 3, 2021
Citation in opposition procedure - 013
Aug 3, 2021
Notice of opposition
Aug 3, 2021
Notice of opposition
Nov 16, 2020
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Oct 8, 2020
Decision to grant a European patent
Sep 15, 2020
Communication regarding the forthcoming grant
Sep 9, 2020
(Electronic) Receipt
Sep 9, 2020
Filing of the translations of the claims
Sep 9, 2020
French translation of claims
Sep 9, 2020
German translation of the claims
Sep 9, 2020
Letter accompanying subsequently filed items
May 28, 2020
Bibliographic data of the European patent application
May 28, 2020
Communication about intention to grant a European patent
May 28, 2020
Intention to grant (signatures)
May 28, 2020
Intention to grant (signatures)
May 28, 2020
Text intended for grant (clean copy)
May 28, 2020
Text intended for grant (sequence listing)
May 28, 2020
Text intended for grant (version for approval)
Mar 23, 2020
(Electronic) Receipt
Mar 23, 2020
Amended description with annotations
Mar 23, 2020
Description
Mar 23, 2020
Letter accompanying subsequently filed items
Mar 23, 2020
Reply to communication from the Examining Division
Mar 17, 2020
Annex to the communication
Mar 17, 2020
Communication from the Examining Division
Dec 9, 2019
Decision to allow further processing
Nov 28, 2019
(Electronic) Receipt
Nov 28, 2019
Amended claims with annotations
Nov 28, 2019
Annex
Nov 28, 2019
Annex
Nov 28, 2019
Annex
Nov 28, 2019
Annex
Nov 28, 2019
Claims
Nov 28, 2019
Letter accompanying subsequently filed items
Nov 28, 2019
Request for further processing
Oct 21, 2019
Application deemed to be withdrawn (no reply to communication from the Examining Division)
Jul 11, 2019
Grant of extension of time limit (examination procedure)
Jul 5, 2019
(Electronic) Receipt
Jul 5, 2019
Letter accompanying subsequently filed items
Jul 5, 2019
Request for extension of time limit to communication from the Examining Division
Mar 12, 2019
Annex to the communication
Mar 12, 2019
Communication from the Examining Division
Jan 10, 2019
(Electronic) Receipt
Jan 10, 2019
Amended claims with annotations
Jan 10, 2019
Claims
Jan 10, 2019
Letter accompanying subsequently filed items
Jan 10, 2019
Non-patent literature cited during the examination procedure
Jan 10, 2019
Reply to communication from the Examining Division
Oct 25, 2018
Grant of extension of time limit (examination procedure)
Oct 22, 2018
(Electronic) Receipt
Oct 22, 2018
Letter accompanying subsequently filed items
Oct 22, 2018
Request for extension of time limit to communication from the Examining Division
Jul 4, 2018
Annex to a communication
Jul 4, 2018
Annex to the communication
Jul 4, 2018
Communication from the Examining Division
May 17, 2018
Miscellaneous requests concerning client data
Apr 11, 2018
Communication confirming withdrawal from representation
Apr 11, 2018
Communication of amended entries concerning the representative
Apr 10, 2018
(Electronic) Receipt
Apr 10, 2018
Amended claims with annotations
Apr 10, 2018
Claims
Apr 10, 2018
Letter accompanying subsequently filed items
Apr 10, 2018
Reply to communication from the Examining Division
Mar 30, 2018
(Electronic) Receipt
Mar 30, 2018
Letter accompanying subsequently filed items
Mar 30, 2018
Submission concerning representation
Feb 16, 2018
Annex to the communication
Feb 16, 2018
Communication from the Examining Division
Feb 12, 2018
Examination started
Jun 21, 2017
Notification on forthcoming publication of bibliographic data
May 22, 2017
Invitation to indicate correct address of inventor
May 16, 2017
Letter which had not been notified
Apr 24, 2017
Communication regarding comments on written opinion/amendment of application/payment of claims fee
Apr 18, 2017
Communication to designated inventor
Apr 18, 2017
Communication to designated inventor
Apr 18, 2017
Communication to designated inventor
Apr 3, 2017
(Electronic) Receipt
Apr 3, 2017
Amended claims filed after receipt of (European) search report
Apr 3, 2017
Amended claims with annotations
Apr 3, 2017
Amendments received before examination
Apr 3, 2017
Request for entry into the European phase
Mar 28, 2017
Copy of the international preliminary report on patentability
Jan 20, 2017
Information on entry into European phase
Apr 5, 2016
Priority document (electronically transmitted)
Mar 17, 2016
Converted Sequence Listing
Mar 17, 2016
Copy of the international search report
Mar 17, 2016
Published international application - A1
Nov 23, 2015
Written opinion of the ISA, boxes No. I to VIII
Nov 23, 2015
Written opinion of the ISA, cover sheet
Nov 23, 2015
Written opinion of the ISA, supplemental box
Sep 22, 2015
Notification of the international application number and of the international filing date
Sep 9, 2015
(Electronic) Receipt
Sep 9, 2015
Abstract
Sep 9, 2015
Claims
Sep 9, 2015
Description
Sep 9, 2015
Document concerning fees and payments
Sep 9, 2015
Drawings
Sep 9, 2015
Electronic request for grant of an International application

EP3191517

INNATE PHARMA

Application Number: EP15762562A
Filing Date: Sep 9, 2015
Status: Revoked; Jun 16, 2023
Publication Date: Nov 4, 2020
External Links: Slate, Register , Google Patents

IP Verse

Cross Reactive Siglec Antibodies

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP3191517